-- 長春高新技術產業股份有限公司（深交所代號：000661）旗下子公司長春基因醫藥股份有限公司的GenSci155注射臨床試驗申請已獲中國監管機構核准。 根據週四提交給深圳證券交易所的文件，該藥物適用於預防早產兒支氣管肺發育不良和治療急性缺血性腦卒中。
Related Articles
Asia
ScinoPharm Taiwan Logs NT$16.5 Million Profit in Q1
ScinoPharm Taiwan (TPE:1789) posted a profit attributable to owners of NT$16.5 million, or NT$0.02 per share, in the first quarter of the year, according to a Wednesday Taiwan bourse filing.Shares slid over 2% in Thursday's midday trade.Operating revenue stood at NT$659.7 million, the pharmaceutical company said.The company did not provide comparative year-ago figures.
$TPE:1789
Asia
Kina Securities Lists Papua New Guinea's First Wholesale Corporate Bond
Kina Securities' (ASX:KSL) 235 million Papua New Guinean Kina, 10-year unsecured subordinated wholesale corporate bond was listed on PNGX Markets, the operator of Papua New Guinea's national stock exchange, on Wednesday, according to a Thursday Australian bourse filing.This represents Papua New Guinea's first listed wholesale corporate bond.The firm expects the issuance to support its balance sheet strength, capital management objectives, and the growth of its banking and financial services operations.Its shares rose 1% in recent trading on Thursday.
$ASX:KSL
Asia
Home First Q4 Profit Soars to INR 1.5 Billion, Beats Estimates
Home First Finance Company India's (NSE:HOMEFIRST, BOM:543259) profit after tax rose to 1.49 billion Indian rupees in the fiscal fourth quarter ended March 31, from 1.05 billion rupees a year ago.Earnings per share came in at 14.22 rupees from 11.45 rupees a year ago, the financial services provider said in a filing to the Indian stock exchanges on Wednesday. The EPS was higher than the 14.08 rupees estimated by the analysts polled by Visible Alpha.Total revenue from operations also increased to 5.01 billion rupees from 2.15 billion rupees a year ago.The company's board recommended a dividend of 5.20 rupees per share of a face value of 2 rupees each for the financial year ended March 31.The company's shares were down 2% in recent trade.
$BOM:543259$NSE:HOMEFIRST